BioCentriq, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, has named Syed T. Husain as its new Chief Executive Officer and member of the Board of Directors.
With over 20 years of leadership experience in the CDMO sector, particularly in cell and gene therapies, Syed has successfully led companies through periods of rapid growth and innovation. His expertise spans global strategy development, market expansion, and operational efficiency improvements. His appointment is a significant milestone for BioCentriq as the company aims to expand its services and advance the commercialization of innovative therapies.
In his new role, Syed will guide BioCentriq through its next growth phase, positioning the company to support pharmaceutical and biotech clients as they transition from pivotal trials to commercial manufacturing. Drawing on his recent experience as Chief Commercial Officer at Resilience, where he built a robust commercial organization and secured major deals with leading pharma and biotech firms, Syed is well-prepared to lead BioCentriq’s expansion. His previous roles at CDMOs like Emergent BioSolutions, Alcami Corporation, and Lonza further underscore his deep industry expertise.
About BioCentriq
BioCentriq is a leading cell therapy contract development and manufacturing organization. Since 2022, the company has been dedicated to developing, manufacturing, and releasing GMP autologous and allogeneic cell therapies. Known for its expertise, BioCentriq specializes in early- to mid-stage therapies with an aim to expand to an end to end – clinical to commercial offering. It operates out of two U.S.-based manufacturing facilities. BioCentriq combines the flexibility and entrepreneurship of a specialist CDMO with the backing of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.
